

### **Conference Cochairs:**

Peter J. Allen, Duke University School of Medicine, Durham, NC  
Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA  
Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE  
Alec C. Kimmelman, NYU Langone Health, New York, NY

### **SUNDAY, SEPTEMBER 15**

#### **Registration**

3-8 p.m. | America Ballroom Foyer

#### **Welcome and Keynote Lectures**

5:30-7:15 p.m. | American Ballroom Center & North | CME Eligible

- |           |  |
|-----------|--|
| 5:30-5:45 | Welcome<br>Peter J. Allen, Duke University School of Medicine, Durham, NC  |
| 5:45-5:50 | Introduction of Keynote Speaker<br>Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA   |
| 5:50-6:30 | Pancreas Cancer 2024: Translating genomic findings into clinical actionability<br>Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY |
| 6:30-6:35 | Introduction of Rising Star Keynote Speaker<br>Alec C. Kimmelman, NYU Langone Health, New York, NY   |
| 6:35-7:15 | Targeting autophagy in pancreatic cancer<br>Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, MA  |

#### **Lightning Presentation Session A**

7:20-7:40 p.m. | American Ballroom Center & North | CME Eligible

- |           |   |
|-----------|---|
| 7:20-7:25 | Introduction of Lightning Presentation Speakers<br>Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE  |
| 7:25-7:27 | Systemic targeting of therapeutic RNA to pancreatic ductal adenocarcinoma via a novel, cell-penetrating, and nucleic acid-binding monoclonal antibody<br>Diana Martinez-Saucedo, Yale University School of Medicine, New Haven, CT* |

\* talk from proffered paper



- 7:28-7:30      Uncovering molecular differences in pancreatic ductal adenocarcinoma tissues from Black and White patients in the US  
 Saurabh Mandal, Henry Ford Health, Detroit, MI\*
  
- 7:31-7:33      Canonical Notch signaling in cancer-associated fibroblasts supports an immunosuppressive pancreatic tumor microenvironment  
 Allison Bischoff, University of Michigan, Ann Arbor, MI\*
  
- 7:34-7:36      Phase 2 trial testing the PARP inhibitor Niraparib in patients with advanced pancreatic cancer with pathogenic variants in *BRCA 1*, *BRCA2*, *PALB2*, *ATM*, and *CHEK2*  
 Brandon Huffman, Dana-Farber Cancer Institute, Boston, MA\*

**Poster Session A / Reception**

7:45-10 p.m. | American Ballroom South

**MONDAY, SEPTEMBER 16**

**Continental Breakfast**

7-8 a.m. | Essex Ballroom (3<sup>rd</sup> Floor)

**Career Development Roundtable Session**

7-8 a.m. | Essex Ballroom (3<sup>rd</sup> Floor) | Not CME Eligible

*Attendance to each of the Career Roundtables will be on a first-come, first-served basis and no pre-registration is required. Participants may rotate to as many tables as they like during the session, providing the opportunity to network and interact with a diverse cadre of experts.*

<p><b>Balancing Clinical and Research Life</b>          Jashodeep Datta, University of Miami Miller School of Medicine, Miami, FL</p>	<p><b>How to Get a Paper Published</b>          Cosimo Commisso, Sanford Burnham Prebys, San Diego, CA          Harmony Turk, <i>Cancer Research</i>, American Association for Cancer Research, Philadelphia, PA</p>
<p><b>Balancing Clinical and Research Life</b>          Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY</p>	<p><b>How to Get a Paper Published</b>          Teresa A. Zimmers, Oregon Health &amp; Science University Knight Cancer Institute, Portland, OR</p>

\* talk from proffered paper



<p><b>Careers in Industry</b>          Mallika Singh, Revolution Medicines, Redwood City, CA</p>	<p><b>How to Write a Grant</b>          Kirsten Bryant, University of North Carolina, Chapel Hill, NC</p>
<p><b>Choosing a Career Path: Academia vs. Industry</b>          Channing Der, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC</p>	<p><b>How to Write a Grant</b>          Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI</p>
<p><b>Collaborating with Industry</b>          Eileen M. O'Reilly, Memorial Sloan Kettering Cancer Center, New York, NY</p>	<p><b>Starting Your Lab</b>          Joseph D. Mancias, Dana-Farber Cancer Institute, Boston, MA</p>
	<p><b>Starting Your Lab</b>          Erica D. Pratt, Boston University, Boston, MA</p>


**Plenary Session 1: Cachexia, Diet, and Metabolism**

8:15-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Peter J. Allen, Duke University School of Medicine, Durham, NC

8:15-8:20	Introduction Peter J. Allen
8:20-8:40	Mechanisms of pancreatic cancer cachexia Teresa A. Zimmers, Oregon Health & Science University Knight Cancer Institute, Portland, OR
8:40-8:45	Discussion / Q&A
8:45-9:05	Developing therapies for pancreatic cancer cachexia Andrew E. Hendifar, Cedars Sinai Medical Center, Los Angeles, CA
9:05-9:10	Discussion / Q&A
9:10-9:30	Neuroendocrine causes and effects of cachexia Tobias Janowitz, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
9:30-9:35	Discussion / Q&A
9:35-9:45	Endocrine beta-cell stress promotes pancreatic ductal adenocarcinoma through endocrine-exocrine cell crosstalk Cathy Garcia, Yale University, New Haven, CT*

\* talk from proffered paper



9:45-9:55 Dietary fats dictate pancreatic cancer fate via phospholipid saturation  
Christian Ruiz, Yale University, New Haven, CT\*

**Break**

9:55-10:30 a.m. | American Ballroom Foyer

**Plenary Session 2: Immunology and Immunotherapy**

10:30 a.m.-12:10 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, NY

- 10:30-10:35 Introduction  
Alec C. Kimmelman
- 10:35-10:55 The tumor-reactive CD8+ T-cell repertoire in pancreatic cancer as  
revealed by single-cell sequencing  
Rienk Offringa, German Cancer Research Center, Heidelberg, Germany
- 10:55-11 Discussion / Q&A
- 11-11:20 Investigating the role of CD4 T cells in the pancreatic tumor  
microenvironment  
Katelyn T. Byrne, Oregon Health and Science University, Portland, OR
- 11:20-11:25 Discussion / Q&A
- 11:25-11:45 Exploiting functional specialization of myeloid-derived suppressor cells to  
overcome therapeutic resistance in pancreatic cancer  
Jashodeep Datta, University of Miami Miller School of Medicine, Miami,  
FL
- 11:45-11:50 Discussion / Q&A
- 11:50-12 Discovery and therapeutic potential of novel cryptic peptides in pancreatic  
cancer  
Gurcan Gunaydin, Dana-Farber Cancer Institute, Boston, MA\*
- 12:00-12:10 Reprogramming and selective recruitment of distinct neutrophil  
subpopulations restrain cancer metastasis  
Jae Lee, Johns Hopkins University School of Medicine, Baltimore, MD\*

**Lunch on Own**

12:10-2:30 p.m.

\* talk from proffered paper



### **Plenary Session 3: Stromal Aspects of the Microenvironment and Tumor Microenvironment**

2:30-4:10 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center,  
Omaha, NE


- |           |   |
|-----------|---|
| 2:30-2:35 | Introduction<br>Michael A. (Tony) Hollingsworth   |
| 2:35-2:55 | Functional heterogeneity of fibroblast populations in pancreatic cancer<br>Giulia Biffi, Cancer Research UK Cambridge Institute, Cambridge, United Kingdom  |
| 2:55-3    | Discussion / Q&A  |
| 3-3:20    | Mechanisms and consequences of pancreatic cancer stromal evolution<br>Mara Sherman, Memorial Sloan Kettering Cancer Center, New York, NY  |
| 3:20-3:25 | Discussion / Q&A  |
| 3:25-3:45 | Targeting the tumor microenvironment to improve responses to therapy<br>David G. DeNardo, Washington University School of Medicine in St. Louis, St. Louis, MO  |
| 3:45-3:50 | Discussion / Q&A  |
| 3:50-4    | Temporally resolved proteomics identifies nidogen-2 as a co-target in pancreatic cancer that modulates fibrosis and therapy response<br>Paul Timpson, The Garvan Institute of Medical Research, Sydney, NSW, Australia*   |
| 4-4:10    | Phase 1b study of maintenance soluble beta-glucan (Odetiglucon) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma that had not progressed on first-line chemotherapy<br>Max Wattenberg, University of Pennsylvania, Philadelphia, PA* |

### **Lightning Presentation Session B**

4:15-4:35 p.m. | American Ballroom Center & North | CME Eligible

- |           |  |
|-----------|--|
| 4:15-4:20 | Introduction of Lightning Presentation Speakers<br>Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA                   |
| 4:20-4:22 | Altered mRNA splicing mimics chromosome loss and drives pancreatic cancer<br>Natasha Pinto Medici, Yale University, New Haven, CT* |

\* talk from proffered paper



- 4:23-4:25      The circadian rhythm gene *Dec2* regulates multiple components of the antigen presentation pathway to promote pancreatic cancer dormancy by immune evasion  
Chris Harris, University of Rochester Medical Center, Rochester, NY\*
- 4:26-4:29      Disruption of sulfatide metabolism by targeting UGT8 is actionable metabolic vulnerability for pancreatic cancer early interception  
Riccardo Ballaro, The University of Texas MD Anderson Cancer Center, Houston, TX\*
- 4:30-4:32      Meta-analysis of spatial transcriptomics data from pancreatic cancer precursors propose a common molecular framework for PanIN and IPMN  
Matthew Iyer, University of Michigan, Ann Arbor, MI\*

### **Poster Session B / Reception**

4:45-7 p.m. | American Ballroom South

### **Dinner on Own**

7 p.m.

## **TUESDAY, SEPTEMBER 17**

### **Continental Breakfast**

7-8 a.m. | Essex Ballroom (3<sup>rd</sup> Floor)

### **Plenary Session 4: KRAS Resistance, Mechanisms, and Therapeutics**


8:15-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, NY

- 8:15-8:20      Introduction  
Alec C. Kimmelman
- 8:20-8:40      Mechanisms of resistance to oncogenic KRAS inhibition in pancreatic cancer  
Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA
- 8:40-8:45      Discussion / Q&A
- 8:45-9:05      Adaptation and resistance to pan-RAS inhibition in pancreatic ductal adenocarcinoma  
Kenneth P. Olive, Columbia University Irving Medical Center, New York, NY
- 9:05-9:10      Discussion / Q&A

*\* talk from proffered paper*





- 9:10-9:30 Targeting the oncogenic state of RAS with tri-complex inhibitors  
Mallika Singh, Revolution Medicines, Redwood City, CA
- 9:30-9:35 Discussion / Q&A
- 9:35-9:45 Identifying synergistic combinations with KRAS inhibition in PDAC  
Fredrik Thege, The University of Texas MD Anderson Cancer Center,  
Houston, TX\*
- 9:45-9:55 Evaluating direct KRAS<sup>Q61H</sup> inhibition in pancreatic cancer models  
Andrew Waters, University of Cincinnati, Cincinnati, OH\*

### Break

9:55-10:30 a.m. | American Ballroom Foyer

### Plenary Session 5: KRAS Cell Biology

10:30-11:50 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center,  
Omaha, NE

- 10:30-10:35 Introduction  
Michael A. (Tony) Hollingsworth
- 10:35-10:55 Targeting KRAS for pancreatic cancer treatment  
Channing Der, University of North Carolina Lineberger Comprehensive  
Cancer Center, Chapel Hill, NC
- 10:55-11 Discussion / Q&A
- 11-11:20 Elucidation of metabolic resistance mechanisms to RAS inhibition  
Kirsten Bryant, University of North Carolina, Chapel Hill, NC
- 11:20-11:25 Discussion / Q&A
- 11:25-11:45 RAS mutation tropism: Insight into tumor initiation  
Christopher M. Counter, Duke University School of Medicine, Durham,  
NC
- 11:45-11:50 Discussion / Q&A

### Lunch on Own / Free Time

11:50 a.m.-2:30 p.m.

\* talk from proffered paper



### **Plenary Session 6: Early Detection and Interception of Precursor Lesions**

2:30-4:15 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Peter J. Allen, Duke University School of Medicine, Durham, NC

- |           |   |
|-----------|---|
| 2:30-2:35 | Introduction<br>Peter J. Allen  |
| 2:35-2:55 | Prevention of pancreatic cancer: The opportunity of intraductal papillary mucinous neoplasms<br>Peter J. Allen  |
| 2:55-3    | Discussion / Q&A  |
| 3-3:20    | Multimodal tools for noninvasive cancer monitoring<br>Erica D. Pratt, Boston University, Boston, MA   |
| 3:20-3:25 | Discussion / Q&A  |
| 3:25-3:45 | Improving pancreatic cancer early detection using a tumor marker gene test<br>Michael G. Goggins, Johns Hopkins University, Baltimore, MD                               |
| 3:45-3:55 | Discussion / Q&A  |
| 3:55-4:05 | Genomic and transcriptomic characterization of pancreatic cancer patients on the PASS-01 trial<br>Grainne O’Kane, Princess Margaret Cancer Centre, Toronto, ON, Canada* |
| 4:05-4:15 | Tracing pancreatic cancer through space<br>Eileen Carpenter, University of Michigan, Ann Arbor, MI  |

### **Break**

4:15-4:35 p.m. | American Ballroom Foyer

### **Plenary Session 7: Tumor Cell Biology**

4:35-6 p.m. | American Ballroom Center & North | CME Eligible

Session Chair: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

- |           |   |
|-----------|---|
| 4:35-4:40 | Introduction<br>Michael A. (Tony) Hollingsworth   |
| 4:40-5    | Syndecan 1 is a therapeutic target for KRAS-driven pancreatic cancer<br>Wantong Yao, The University of Texas MD Anderson Cancer Center, Houston, TX |

\* talk from proffered paper





- 5-5:10 Discussion / Q&A
- 5:10-5:30 Stress-induced O-glycans drive immunosuppression in pancreatic cancer  
Tobiloba Oni, Whitehead Institute, Cambridge, MA
- 5:30-5:35 Discussion / Q&A
- 5:35-5:55 Metabolic adaptations to autophagy inhibition in PDAC  
Christina Towers, The Salk Institute for Biological Studies, La Jolla, CA
- 5:55-6 Discussion / Q&A

### Lightning Presentation Session C

6-6:15 p.m. | American Ballroom Center & North | CME Eligible

- 6-6:05 Introduction of Lightning Presentation Speakers  
Peter J. Allen, Duke University School of Medicine, Durham, NC
- 6:05-6:07 RNF43 loss induces an IRE1-dependent metabolic reprogramming in  
pancreatic cystic neoplasms  
Akiko Sagara, The University of Texas MD Anderson Cancer Center,  
Houston, TX\*
- 6:08-6:10 Cell polarity proteins as novel regulators of macropinocytosis  
Guillem Lambies Barjau, Sanford Burnham Prebys Medical Discovery  
Institute, La Jolla, CA\*
- 6:11-6:13 Hepcidin-mediated iron sequestration limits CD8<sup>+</sup> tumor infiltrating  
lymphocytes in pancreas adenocarcinoma  
Joshua Schoenfeld, Memorial Sloan Kettering Cancer Center, New York,  
NY\*

### Poster Session C / Reception

6:30-9 p.m. | American Ballroom South

## WEDNESDAY, SEPTEMBER 18

### Continental Breakfast

7-8 a.m. | Essex Ballroom (3<sup>rd</sup> Floor)

### Plenary Session 8: Plasticity

8-9:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Stephanie K. Dougan, Dana-Farber Cancer Institute, Boston, MA

- 8-8:20 TGFb in pancreatic cancer  
Stephanie K. Dougan

\* talk from proffered paper



8:20-8:25	Discussion / Q&A
8:25-8:45	Regulation of tumor and stromal cell plasticity by metabolic stress Cosimo Commisso, Sanford Burnham Prebys, San Diego, CA
8:45-8:50	Discussion / Q&A
8:50-9:10	The role of methionine oxidation in pancreatic tumorigenesis Christine Chio, Columbia University, New York, NY
9:10-9:15	Discussion / Q&A
9:15-9:35	PDAC proteomic subtype specification through the lens of racial health disparities Nicholas T. Woods, University of Nebraska Medical Center, Omaha, NE
9:35-9:40	Discussion / Q&A
9:40-9:50	Temporal stability and chemotherapy responsiveness of classical and basal transcriptional subtypes of pancreatic cancer Harshabad Singh, Dana-Farber Cancer Institute, Boston, MA*
9:50-9:55	Discussion / Q&A

### Break

9:55-10:15 a.m. | American Ballroom Foyer


### Plenary Session 9: Metabolism

10:15-11:55 a.m. | American Ballroom Center & North | CME Eligible

Session Chair: Alec C. Kimmelman, NYU Langone Health, New York, NY

10:15-10:20	Introduction Alec C. Kimmelman
10:20-10:40	Identifying metabolic dependencies in pancreatic cancer Alec C. Kimmelman
10:40-10:45	Discussion / Q&A
10:45-11:05	Spatiotemporal metabolic networks in pancreatic cancer and associated cachexia Nada Kalaany, Harvard Medical School / Boston Children's Hospital, Boston, MA
11:05-11:10	Discussion / Q&A
11:10-11:30	Targeting lipid metabolism in pancreatic cancer Costas A. Lyssiotis, University of Michigan Medical School, Ann Arbor, MI
11:30-11:35	Discussion / Q&A

\* talk from proffered paper



- 11:35-11:50 Metabolic competition in pancreatic tumor microenvironment regulates innate immune responses  
Kamiya Mehla, University of Oklahoma Health Sciences Center, Oklahoma City, OK
- 11:50-11:55 Discussion / Q&A

**Debate: Have We Learned Anything from the KRAS Inhibitors That We Didn't Already Know from Mice?**

12:00-12:45 p.m. | American Ballroom Center & North | CME Eligible

Moderator: Michael A. (Tony) Hollingsworth, University of Nebraska Medical Center, Omaha, NE

Andrew Aguirre, Dana-Farber Cancer Institute, Boston, MA  
Marina Pasca Di Magliano, University of Michigan, Ann Arbor, MI

**Departure**

12:45 p.m.

*\* talk from proffered paper*